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Introduction
These are exciting times! I say this fully recognizing that,
by their very nature, scientists think “their time” is ex-
ceptional. For example, consider this comment: “We live
in a revolutionary age. Our science has caught the spirit
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of the times, and more improvements have been made in
all its branches in the last 20 years than have been made
in a century before,” made by Benjamin Rush in 1791!
Or this one by our own L. C. Dunn, who opened his
presidential address to the members of the ASHG in
1961 with the observation that “There is, I believe, gen-
eral agreement that interest and activity in human ge-
netics has today reached a peak never before attained.”
(Dunn 1962, p. 1).
So let me defend my assertion. In this year, 2003, we
celebrate only the 59th anniversary of the demonstra-
tion by Avery, McCloud, and McCarty that DNA is the
stuff that genes are made of (Avery et al. 1944). We also
celebrate the 50th anniversary of the discovery of the
double helical, antiparallel, complementary nature of
DNA structure by JamesWatson and Francis Crick (Wat-
son and Crick 1953). The chemical consequences of the
complementary structure of DNA underlie much that we
do today in molecular biology and genomics. And, ﬁ-
nally, in 2003, we marked the completion of the “ﬁn-
ished sequence” of the human genome. A draft sequence
of our genome was published in 2001 in papers that
were monumental in both content and length (Inter-
national Human Genome Sequencing Consortium 2001;
Venter et al. 2001). Now, we have a ﬁnished copy that
is being published chromosome by chromosome, with
the most recent, chromosome 6, appearing just two
weeks ago, in Nature, by Jane Rodgers and her col-
leagues from The Sanger Institute (Mungall et al. 2003).
In addition to these landmark achievements in gen-
omics, human geneticists have been busy developing
molecular and other resources that are changing theway
we do clinical genetics. The list of disease genes contin-
ues to increase at a dizzying pace. Currently, OMIM
lists ∼1,500 identiﬁed disease genes, and GeneTests lists
just over 1,000 diseases for which there are molecular
tests, 650 of which are clinically available. Not to be
outdone, the diagnostic precision and sensitivity of cy-
togenetics is improving rapidly with increasing use of
molecular probes and related resources (The BAC Re-
source Consortium 2001; Albertson and Pinkel 2003;
Albertson et al. 2003). In the clinic, rather than making
diagnoses by goodness of ﬁt of phenotypic features to
a mythical classic case, we increasingly rely on precise
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Table 1
Individuality: Levels of Interest
Biologic—variation, selection, and evolution
Genetic—phenotypic differences
Medical—outliers comprise our patients
Clinical/Epidemiological—prevention
molecular assays. As a consequence, we provide our pa-
tients and their families more accurate diagnosis and
prognosis, together with more informed and effective
management. Importantly, human geneticists are also
deeply engaged in the thorny problems of how best to
acquire and utilize genetic information in ways that
maximize the beneﬁts andminimize the potential formis-
use (Foster and Sharp 2000; Clayton 2003).
These amazing accomplishments in genomics and ge-
netics and the vista of opportunities they make available
justify my assertion that our time is truly revolutionary.
We are all privileged to be participants.
The Challenge
But with opportunity comes challenge, as emphasized
in a recent paper by Susan Haga and her colleagues con-
cerning “Genomic Proﬁling” (Haga et al. 2003). The au-
thors deﬁne genomic proﬁling as the concurrent detection
of multiple gene variants associated with greater risk for
or predisposition to disease, for the purpose of recom-
mending speciﬁc risk-reducing actions appropriate for
the at-risk individual. This sounds like what we all hope
to achieve, but there are problems in applying this ap-
proach at our current level of knowledge. In addition to
the epidemiological concerns of poor test validation and
lack of rigorous outcome evaluation, Haga et al. em-
phasize a fundamental biological problem: “the vastness
of the genome and high degree of individual variabil-
ity…creates substantial challenges to identifying which
gene or set of genes combines with nongenetic experi-
ences to produce a disease phenotype” (Haga et al. 2003,
p. 349).
I would restate this simply by saying that we do not
know enough about individuality. In this context, I deﬁne
“individuality” as the biological qualities that distinguish
one person from another. These include variations inbodi-
ly or cellular structure or function and in homeostasis and
adaptation. These are all properties mediated by pro-
teins, which themselves express the individuality of the
genes that specify them. Thus, the root of individu-
ality expressed in these terms is genetic.*
One exciting consequence of the progress in our ﬁeld
is that we are beginning to be able to identify the genetic
differences contributing to individuality. As an extreme
example, consider the olfactory system. Earlier this year,
Menashe and colleagues at the Weizmann Institute se-
quenced 26 human olfactory receptor genes chosen from
a subset of the total of ∼500 such functional genes in
our genome because they were polymorphic for inacti-
vatingmutations. Among 189 individuals sequenced, they
found 178 (94%) with unique functional combinations
* This deﬁnition grew out of a graduate-level seminar course in Hu-
man Genetics taught by Barton Childs and me.
(Menashe et al. 2003). The take-home message from
genotyping even this small subset of olfactory receptors
is that no two people perceive the environment of odor-
ants in the same way. Less extreme but equally poly-
morphic variation has been described at the molecular
level for taste (Dulac 2000; Kim et al. 2003) and vision
(Nathans 1994). This high level of inherited variation
in the proteins we use to sample our environment plays
out in a constellation of experiences also unique for each
individual, conﬁrming what law enforcement agents and
lawyers who deal with “eye witnesses” have learned:
perception of the world around us is highly individual.
Why Individuality?
Aside from its being the “spice of life,” why are we
interested in individual variation (table 1)?
First is a biologic reason: individual variation and se-
lection are at the center of evolution, and, as Dobzhan-
sky famously told us, “Nothing in biology makes sense
except in the light of evolution” (Dobzhansky 1973, p.
125). So, if we want to understand where we came from
and how evolutionary forces continue to shape our spe-
cies, we must understand the origins and consequences
of individuality.
Second, at the level of genetics, any casual student of
the human phenotype sees that all of us are different. This
is apparent from the appearance of our face or how we
grow or how we respond to environmental experiences.
As geneticists, we want to understand these differences—
what accounts for them and why.
Third, as physicians, we encounter the outliers—our
patients are those whose individuality results in the in-
ability to develop normally and/or maintain physiologic
homeostasis in response to their particular set of envi-
ronmental experiences. As we become more sophisticated
observers, we recognize that each patient has a personal
phenotype that reﬂects his or her genetic and experiential
individuality (Scriver 2002).
Finally, there is the desirability and challenge of ap-
plying genetics and genomics to preventive medicine, as
we saw in the paper on genomic proﬁling (Haga et al.
2003) and asmany others have emphasized (Collins1999;
Emery and Hayﬂick 2001; Collins et al. 2003).
For all these reasons, I will now considerwhatweknow
about individuality: the history of the development of our
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Figure 1 Archibald Garrod on rounds, early in the 20th century (courtesy Alec Bearn)
ideas, the extant explanatory evidence, and some areas
that seem likely to provide additional, as-yet-unappre-
ciated, reservoirs of human variation.
Historical Context
To provide historical context for our understanding
of individuality, I start, of course, with Sir Archibald E.
Garrod (ﬁg. 1), who started his medical career at Great
Ormond Street Hospital for Sick Children and eventu-
ally (1920) became the Regius Professor of Medicine at
Oxford. Garrod wrote two books; most of us know the
ﬁrst, published in 1909, in which he originated the con-
cept of “inborn errors,” giving this class of disorders the
name we still use today (Garrod 1909). His ideas devel-
oped from astute observations of patients with a handful
of disorders, most notably alkaptonuria. Imagine work-
ing on the crowded hospital wards in Garrod’s time,
surrounded by patients with infectious disease, malnu-
trition, and the like, and developing an interest in al-
kaptonuria, a disorder with a frequency of ∼1/100,000
(LaDu 2001)! Garrod was deeply interested in chemistry,
especially as applied to medicine, and this may explain,
in part, his fascination with inborn errors (Bearn 1993).
He came by this interest honestly; his father, Alfred, was
a rheumatologist and was also interested in the interface
between chemistry and medicine (Garrod 1848). What
set the younger Garrod apart, however, was not so much
his recognition and characterization of these rare dis-
orders but rather his ability to generalize what he learned
from them to all medicine. In his classic 1902 paper in
Lancet, he concluded that alkaptonuria and similar dis-
orders were “merely extreme examples of variations of
chemical behavior which are probably everywhere pre-
sent in minor degrees and that just as no two individuals
of a species are absolutely identical in bodily structure
neither are their chemical processes carried out in exactly
the same lines” (Garrod 1902, p. 1620). In his second
book, Inborn Factors in Disease, published in 1931,
Garrod revealed how his thinking on these ideas had
matured, speaking of “chemical individuality” or the
genetically determined, biochemical characteristics and
capabilities that confer “our predisposition to and im-
munities from the various mishaps which are spoken of
as diseases” (Garrod 1931, p. 157; Childs 1970). Imag-
ine how Garrod would have appreciated the ﬂood of
evidence for the genetic basis of individuality to which
we are privy today.
So why did it take so long for Garrod’s ideas to have
an appreciable effect on medical and genetic thinking? At
the same time Garrod was developing his ideas, genetics
was undergoing impressive growth. In an intellectual tour
de force, T. H. Morgan and his Drosophila geneticists
in the ﬂy room at Columbia were formulating genetic
principles that are still in use today (Kohler 1994). And
yet, for them, the gene was an operational concept, a
unit of mutation, recombination, and function with no
basis in chemistry (Childs 1999). The “wild type” was
monolithic, with little consideration of or means to in-
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Table 2
Estimates of Measures of Genetic Individuality
from Halushka et al. (1999)
∼ -bp differences, or ∼1 cSNP/kb63# 10
∼80%–85% polymorphism at the protein level
∼17% average heterozygosity
vestigate normal variation. Later, in the early ’40s, Bea-
dle and Tatum, in their Nobel Prize–winning work on
the “one gene, one enzyme” concept that provided our
current context for understanding how the information
in the genes relates to the proteins that do the work,
gave little consideration to the idea of individuality (Bea-
dle and Tatum 1941; Beadle 1959).
Genetics ﬁnally began to appreciate the variation nec-
essary to explain Garrod’s “chemical individuality”with
the recognition and enumeration of polymorphic enzyme
variants—simultaneously by Harry Harris in humans and
by Richard Lewontin in ﬂies—in the late 1960s (Lewontin
1974; Harris 1976). With their work and the advances
in genomics and genetics that we are celebrating at this
meeting, our understanding of the genetic basis of in-
dividuality has increased rapidly.
Extant Evidence for Variation
We now appreciate several kinds of mutations or her-
itable changes in the DNA sequence that vary over a wide
range of frequency. In addition to a potentially limitless
number of rare variants, there are several categories of
common mutations or polymorphisms (frequency0.01)
contributing to the 0.1% of our sequence that varies from
one individual to the next (International HumanGenome
Sequencing Consortium 2001; Venter et al. 2001). Chief
among these are the single nucleotide polymorphisms or
SNPs, which number ∼5 million in our genome (dbSNP
Home Page), with other kinds of changes (insertion/de-
letion and length polymorphisms) making up a much
smaller fraction of the variation. Recombination serves
to shufﬂe the sequence variants in limitless combinations
from one generation to the next.
So, given this amount of sequence variation, how dif-
ferent are we are at the level of our genes? Although the
answer to this question is still not known across the entire
genome and in people from all around the globe, theHap-
Map project currently under way should go a long way
toward answering these questions (The International
HapMap Consortium 2003). Until these data are avail-
able, useful estimates come from the work of Halushka
et al. (1999) and Cargill et al. (1999). Both groups per-
formed extensive resequencing of a large number of
genes (76 involved in blood pressure homeostasis in the
former and 106 involved in cardiovascular disease, endo-
crinology, and neuropsychiatry in the latter). The studies
yielded similar results. Table 2 presents the results of
Halushka et al. (1999). Note that the amount of varia-
tion is such that 175% of the proteins were polymorphic
at the level of amino acid sequence; Harry Harris would
certainly have approved.
Potential New Sources of Variation
But is this amount of protein sequence variation suf-
ﬁcient to explain themajor extent of genetic individuality?
And, if not, what are other sources of variation in our
genome? The answers to these questions are nearly in
hand, but I am willing, at this point, to speculate that
there are sources of substantial genetic variation that are
yet relatively underappreciated. In what follows, I will
brieﬂy consider three possible such sources: allelic varia-
tion in gene expression, alternative splicing and its varia-
tions, and epigenetics.
Although there are many reports of promoter muta-
tions altering expression of particular genes to produce
genetic disease (e.g., see Weatherall et al. [2001]), the
ﬁrst systematic survey of allelic variation in expression
of human genes that I am aware of was a short paper
by Kinzler, Vogelstein, and their colleagues (Yan et al.
2002). These investigators used SNPs in the transcripts
of interest to compare the levels of expression of two
“normal alleles” of the same gene in heterozygous in-
dividuals. Among 13 genes studied, roughly half showed
allelic variation in expression, ranging from 1.3- to 4.3-
fold. These expression differences followed Mendelian
segregation in informative CEPH families, indicating that
the responsible variation was cis-acting. A subsequent
study of 603 genes also found that about half showed
signiﬁcant allelic variation in expression ranging from two
to more than fourfold (Lo et al. 2003). Sequence variation
accounting for some of these differences (long-range en-
hancers) detected by a combination of comparative gen-
omics and transgenic assays may be hundreds of kilo-
bases away from the regulated gene (Nobrega et al. 2003).
Additional work on the extent, mechanisms, and con-
sequences of this variation is required, but it could have
substantial effects on our understanding of Mendelian
disease, complex traits, and normal variation. Some of
these consequences are reviewed by Cheung and Spiel-
man (2002).
A second potential major source of variation contrib-
uting to individuality involves the factors that perform
and regulate alternative splicing. Current evidence sug-
gests that 30%–50% or more of our genes undergo al-
ternative splicing, greatly multiplying the protein reper-
toire of our genome (Black 2003). The molecular appa-
ratus for this process includes cis-acting enhancer and
repressor sequences, SR proteins and others that bind to
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these sequences, small ribonuclear proteins that catalyze
the splicing, and others (Black 2003; Jurica and Moore
2003). The extent and consequences of variation in this
complex system are unknown, but the potential for con-
tribution to genetic individuality is large. We do know
that variation in splice enhancer sequences has been
found to contribute to genetic disease (Cartegni and
Krainer 2002; Cartegni et al. 2002; Nurtdinov et al.
2003), and a Web site is available to assist in identifying
these sequences (ESEﬁnder) (Cartegni et al. 2003).
The last of the three possible sources of additional
genetic individuality has to do with epigenetics, or stable
alterations in gene-expression potential that arise during
development and cellular proliferation (Jaenisch and Bird
2003). Imprinting results from differential epigenetic
modiﬁcations that differ depending on the parent of or-
igin. The molecular mechanisms underlying epigenetics
include DNAmethylation and histone modiﬁcations and
have been the subject of several recent reviews (Jones
and Takai 2001; Feinberg et al. 2002; Jaenisch and Bird
2003; Murphy and Jirtle 2003). The picture that is
emerging is a dynamic one, with layers of regulation
affecting the state of chromatin and gene expression
(Jaenisch and Bird 2003).
Increasingly, we are learning how environmental vari-
ables inﬂuence epigenetic regulation. Using coat-color al-
leles at the agouti locus, Wolff and his colleagues have
shown than maternal nutritional variables during preg-
nancy (e.g., methyl donors) can have effects over the life-
time of her pups (Wolff et al. 1998). Moreover, some of
these epigenetic modiﬁcations are not completely erased
during oogenesis and inﬂuence epigenetic regulation in
the next generation (Cooney et al. 2002). Thus, environ-
mental experiences can have profound effects on epige-
netics and contribute to long-term individual variation in
gene expression. We know much less, however, on the
effects and extent of inherited variation on epigenetic
mechanisms. Sapienza and his colleagues have recently
described familial clustering of methylation ratios at cer-
tain imprinted loci and have reviewed the evidence for
individual variation in imprinting (Sandovici et al. 2003).
What is clear is that inherited variation in genes encoding
proteins that perform or regulate epigenetic mechanisms
could have profound effects on genetic individuality. This
area is likely to be a fruitful one for understanding normal
and disease-producing variation (Beaudet 2002).
Variation and Systems
Enumeration of the sources and extent of genetic varia-
tion at each individual locus is only the ﬁrst part of the
story. In the intact organism, proteins are integrated into
complex biological systems (“modules”) that are them-
selves organized into still larger systems (Hartwell et al.
1999; Ravasz et al. 2002). In his book The Logic of Life,
Franc¸ois Jacob called these systems “integrons,” saying
that organisms are built by a series of integrations—“a
hierarchy of integrons” (Jacob 1976, p. 302). To appre-
ciate individuality, we must understand the consequences
of the variation in our genome on the behavior of these
systems; that is, we must understand the structure, dy-
namics, control mechanisms, and design of the myriad
protein modules or integrons required for normal devel-
opment and physiological homeostasis. This challenge,
covered broadly under the heading of “systems biology”
(Kitano 2002a, 2002b), was something geneticists could
hardly envision until the tremendous progress catalyzed
by the Human Genome Project. Whole-genome sequence
essentially provides a complete parts list for all the systems
in an organism, and new technologies—such as the yeast
two-hybrid assay, tandem afﬁnity puriﬁcation, expression
proﬁling, and tandem mass spectrometry—provide tools
to enumerate the interactions (protein-protein, protein-
DNA, and protein-metabolite) characteristic of each sys-
tem (Uetz et al. 2000; Ideker et al. 2001; Ito et al. 2001;
Gavin et al. 2002; Ho et al. 2002). Using these resources,
we have already made considerable progress in under-
standing the structure of biological systems. Baraba´si,Olt-
vai, and their colleagues have found that most biological
systems form highly inhomogeneous, scale-free networks
in which the components, or “nodes,” have widely dif-
ferent connectivities (Albert et al. 2000; Jeong et al. 2000,
2001).Most nodes in such networks have only a few links
to others, whereas a few are highly connected “hubs”
(Baraba´si 2002). Networks constructed in this fashion are
inherently tolerant to variation, buffering perturbations
in ways that allow the system tomaintain acceptable func-
tion (Wagner 2000; Hartman et al. 2001; Jeong et al.
2001). This ability to buffer variation confers a robust
response to errors, enabling such systems to degrade
gracefully rather than catastrophically (Kitano 2002b).
The behavior of biological systems is highly relevant to
our understanding of the consequences of accumulating
“normal” variation and of the pathophysiological mech-
anisms at work in complex traits and monogenic disease.
One challenge for training geneticists of the future is to
entice computationally talented individuals to study the
behavior of biological systems.
Summary
We are fortunate participants in a biomedical revolution;
even better, we are at the edge of the wedge of knowledge
that is driving this revolution. Understanding individu-
ality in terms of its genetic basis, evolutionary origin,
effect on phenotype, and consequences for health is a
central challenge that looms before us. Ultimately, we
must learn how to evaluate and incorporate individuality
into an effective, prospective form of medicine that relies
heavily on prevention.
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The way forward will require interdisciplinary basic
research by investigators with expertise in genetics and
genomics, as well as many other ﬁelds, including com-
putational biology, evolutionary biology, and systems en-
gineering. To bring the advances in basic research to bear
on medical problems, we will need clinical research both
on individuals and on populations. Perhaps these new
opportunities for clinical research will help invigorate
an area of research that we desperately need but that
is currently understaffed (Goldstein and Brown 1997).
Education of our students, our colleagues, and our
patients will continue to be a catalyst for these activities.
For this reason and others, I emphasize the educational
opportunities at hand. You will not be able to walk away
from this meeting without realizing that genetics is a
dynamic, vibrant, and rapidly evolving subject. What
we have to say is relevant to all of biology and medi-
cine—to quote Vogel and Motulsky, “genetics…[is] the
leading basic science of medicine” (Vogel and Motulsky
1997, p. vii). Understanding individuality and applying
this understanding to basic and clinical research as well
as to the practice of medicine promises to be highly
challenging and rewarding.
Acknowledgments
I would like to acknowledge the ASHG staff for their skill,
dedication, and hard work on behalf of our Society. I also
thank my many colleagues and friends in ASHG who have
made this year and my career so rewarding. Finally, I give
special thanks to members of my lab, students, fellows, and
Hopkins colleagues, for useful discussions, and to Sandy Mus-
celli, for help in preparation of this manuscript. Special rec-
ognition is due Barton Childs and the Johns Hopkins Human
Genetics students who participated in a seminar course on
Individuality, from which most of these thoughts are distilled.
Electronic-Database Information
The URLs for data presented herein are as follows:
ESEﬁnder, http://exon.cshl.edu/ESE/
Gene Tests, http://www.genetests.org/
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlmnih.gov/Omim/
dbSNP Home Page, http://www.ncbi.nlm.nih.gov/SNP/
References
Albert R, Jeong H, Baraba´si A-L (2000) Error and attack tol-
erance of complex networks. Nature 406:378–382
Albertson DG, Collins C, McCormick F, Gray JW (2003) Chro-
mosome aberrations in solid tumors. Nat Genet 34:369–376
Albertson DG, Pinkel D (2003) Genomic microarrays in human
genetic disease and cancer. Hum Mol Genet 12:R145–R152
Avery OT, MacLeod CM, McCarty M (1944) Studies on the
chemical nature of the substance inducing transformation of
pneumococcal types. J Exp Med 79:137–158 (Reprinted in
Mol Med 1:344–365)
BAC Resource Consortium, The (2001) Integration of cytoge-
netic landmarks into the draft sequence of the human genome.
Nature 409:953–958
Baraba´si A-L (2002) Linked: the new science of networks. Per-
seus Publishing, Oxford
Beadle GW (1959) Genes and chemical reactions in Neuro-
spora. Science 129:1715–1719
Beadle GW, Tatum EL (1941) Genetic control of biochemical
reactions in Neurospora. Proc Natl Acad Sci USA 27:499–
506
Bearn AG (1993) Archibald Garrod and the individuality of
man. Clarendon Press, New York
Beaudet AL (2002) Is medical genetics neglecting epigenetics?
Genet Med 4:399–402
Black DL (2003)Mechanisms of alternative pre-messengerRNA
splicing. Annu Rev Biochem 72:291–336
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N,
Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L,
Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ,
Lander ES (1999) Characterization of single-nucleotide poly-
morphisms in coding regions of human genes. Nat Genet 22:
231–238
Cartegni L, Chew SL, Krainer AR (2002) Listening to silence
and understanding nonsense: exonic mutations that affect
splicing. Nat Review Genet 3:285–298
Cartegni L, Krainer AR (2002) Disruption of an SF2/ASF-
dependent exonic splicing enhancer in SMN2 causes spinal
muscular atrophy in the absence of SMN1. Nat Genet 30:
377–384
Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003)
ESEﬁnder: a web resource to identify exonic splicing en-
hancers. Nucleic Acids Res 31:3568–3571
Cheung VG, Spielman RS (2002) The genetics of variation in
gene expression. Nat Genet 32:522–525
Childs B (1970) Sir Archibald Garrod’s conception of chemical
individuality: a modern appreciation. N Engl J Med 282:
71–77
——— (1999) Genetic medicine: a logic of disease. Johns Hop-
kins University Press, Baltimore
Clayton EW (2003) Ethical, legal and social implications of
genomic medicine. N Engl J Med 349:562–569
Collins FS (1999) Shattuck lecture: medical and societal con-
sequences of the human genome project. New Engl J Med
341:28–37
Collins FS, Green ED, Guttmacher AE, Guyer MS (2003) A
vision for the future of genomics research. Nature 422:835–
847
Cooney CA, Dave AA, Wolff GL (2002) Maternal metyl sup-
plements in mice affect epigenetic variation and DNA methy-
lation of offspring. J Nutr Suppl 132:2393S–2400S
Dobzhansky T (1973) Nothing in biology makes sense except
in the light of evolution. Am Biol Teacher 35:125–129
Dulac C (2000) The physiology of taste, vintage 2000. Cell 100:
607–610
Dunn LC (1962) Presidential address: cross currents in the
history of human genetics. Am J Hum Genet 14:1–13
380 Am. J. Hum. Genet. 74:374–381, 2004
Emery J, Hayﬂick S (2001) The challenge of integrating genetic
medicine into primary care. Brit Med J 322:1027–1030
Feinberg AP, Oshimua M, Barrett JC (2002) Epigenetic mech-
anisms in human disease. Cancer Res 62:6784–6787
Foster MW, Sharp RR (2000) Genetic research and culturally
speciﬁc risks: one size does not ﬁt all. Trends Genet 16:93–
95
Garrod A (1909) Inborn errors of metabolism: the Croonian
lectures delivered before the Royal College of Physicians of
London in June 1908. Oxford University Press, London
Garrod AB (1848) Observations on certain pathological con-
ditions of the blood and urine in gout, rheumatism and
Bright’s disease. Med Chir Trans 31:83
Garrod AE (1902) The incidence of alkaptonuria, a study in
chemical individuality. Lancet 2:1616–1620
——— (1931) Inborn factors in disease. Oxford University
Press, Oxford
Gavin A-C, Bo¨scheM, Krause R, Grandi P,MarziochM, Bauer
A, Schultz J, et al (2002) Functional organization of the yeast
proteome by systemic analysis of protein complexes. Nature
415:141–147
Goldstein JL, Brown MS (1997) The clinical investigator: be-
witched, bothered and bewildered—but still beloved. J Clin
Invest 99:2803–3812
Haga SB, Khoury MJ, Burke W (2003) Genomic proﬁling to
promote a healthy lifestyle: not ready for prime time. Nat
Genet 34:347–350
Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A,
Cooper R, Lipshutz R, Chakravarti A (1999) Patterns of sin-
gle-nucleotide polymorphisms in candidate genes for blood-
pressure homeostasis. Nat Genet 22:239–247
Harris H (1976) Enzyme variants in human populations. Johns
Hopkins Med J 138:245–252
Hartman JL, Garvik B, Hartwell L (2001) Principles for the
buffering of genetic variation. Science 291:1001–1004
Hartwell LH, Hopﬁeld JJ, Leibler S, Murray AW (1999) From
molecular to modular cell biology. Nature Suppl 402:C47–
C52
Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams S-L,
Millar A, et al (2002) Systematic identiﬁcation of protein
complexes in Saccharomyces cerevisiae by mass spectrom-
etry. Nature 415:180–183
Ideker T, Thorsson V, Ranish JA, Cristmas R, Buhler J, Eng JK,
Bumgarner R, Goodlett DR, Aebersold R, Hood L (2001)
Integrated genomic and proteomic analyses of a systemati-
cally perturbed metabolic network. Science 292:929–936
International HapMap Consortium, The (2003) The interna-
tional HapMap project. Nature 426:789–796
International Human Genome Sequencing Consortium (2001)
Initial sequencing and analysis of the human genome. Nature
409:860–921
Ito T, Chiba T, Ozawa R, Yoshida M, Hattori M, Sakaki Y
(2001) A comprehensive two-hybrid analysis to explore the
yeast protein interactome. Proc Natl Acad Sci USA 98:4569–
4574
Jacob F (1976) The logic of life: a history of hereditary. Ran-
dom House, New York
Jaenisch R, Bird A (2003) Epigenetic regulation of gene ex-
pression: how the genome integrates intrinsic and environ-
mental signals. Nat Genet Suppl 33:245–254
Jeong H, Mason SP, Baraba´si A-L, Oltvai ZN (2001) Lethality
and centrality in protein networks. Nature 411:41–42
Jeong H, Tombor B, Albert R, Oltvai ZN, Baraba´si AL (2000)
The large-scale organization of metabolic networks. Nature
407:651–654
Jones PA, Takai D (2001) The role of DNA methylation in
mammalian epigenetics. Science 293:1068–1070
Jurica MS, Moore MJ (2003) Pre m-RNA splicing: awash in a
sea of proteins. Mol Cell 12:5–14
Kim U-K, Jorgenson E, Coon H, Leppert M, Risch N, Drayna
D (2003) Positional cloning of the human quantitative trait
locus underlying taste sensitivity to phenylthiocarbamide.
Science 299:1221–1223
Kitano H (2002a) Looking beyond the details: a rise in system-
oriented approaches in genetics and molecular biology. Curr
Genet 41:1–10
——— (2002b) Systems biology: a brief overview. Science 295:
1662–1664
Kohler RE (1994) Lords of the ﬂy: Drosophila genetics and
the experimental life. University of Chicago Press, Chicago
LaDu BN (2001) Alkaptonuria. In: Scriver CR, Beaudet AL, Sly
WS, Valle D (eds) The metabolic and molecular bases of in-
herited disease. McGraw Hill, New York, pp 2109–2123
Lewontin RC (1974) The problem of genetic diversity. Harvey
Lect 2896:1–20
Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, Lee MP
(2003) Allelic variation in gene expression is common in the
human genome. Genome Res 13:1855–1862
Menashe I, Man O, Lancet D, Gilad Y (2003) Different noses
for different people. Nat Genet 34:143–144
Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst J,
Wilming L, Jones MC, et al (2003) The DNA sequence and
analysis of human chromosome 6. Nature 425:805–811
Murphy SK, Jirtle RL (2003) Imprinting evolution and the
price of silence. BioEssays 25:577–588
Nathans J (1994) In the eye of the beholder: visual pigments
and inherited variation in human vision. Cell 78:357–360
Nobrega MA, Ovcharenko I, Afzal V, Rubin EM (2003) Scan-
ning human gene deserts for long-range enhancers. Science
302:413
Nurtdinov RN, Artamonova II, Mironov AA, Gelfand MS
(2003) Low conservation of alternative splicing patterns in
the human and mouse genomes. Hum Mol Genet 12:1313–
1320
Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Baraba´si A-L
(2002) Hierarchial organization of modularity in metabolic
networks. Science 297:1551–1555
Sandovici I, Leppert M, Hawk PR, Suarez A, Linares Y, Sapi-
enza C (2003) Familial aggregation of abnormalmethylation
of parental alleles at the IGF IGF2R differentiallymethylated
regions. Hum Mol Genet 12:1569–1578
Scriver CR (2002) Why mutation analysis does not always pre-
dict clinical consequences: explanation in the era of genomics.
J Pediatr 140:502–506
Uetz P, Giot L, Cagney G, Mansﬁeld TA, Judson RS, Knight JR,
Lockshon D, Narayan V, Srinivasan M, Pochart P, Qureshi-
Emili A, Li Y, Godwin B, Conover D, Kalbﬂeisch T, Vijay-
adamodar G, Yang M, Johnston M, Fields S, Rothberg JM
(2000) A comprehensive analysis of protein-protein inter-
actions in Saccharomyces cerevisiae. Nature 403:623–627
Valle: Genetics, Individuality, and Medicine in the 21st Century 381
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton
GG, Smith HO, et al (2001) The sequence of the human
genome. Science 291:1304–1351
Vogel F, Motulsky AG (1997) Human genetics: problems and
approaches. Springer-Verlag, Heidelberg
Wagner A (2000) Robustness against mutations in genetic net-
works of yeast. Nat Genet 24:355–361
Watson JD, Crick FHC (1953) Molecular structure of nucleic
acids. Nature 171:737–738
Weatherall DJ, Clegg JB, Higgs DR, Wood WG (2001) The
hemoglobinopathies. In: Scriver CR, Beaudet AL, Sly WS,
Valle D (eds) The metabolic and molecular bases of inherited
disease. McGraw Hill, New York, pp 4571–4636
Wolff GL, Kodell RL, Moore SR, Cooney CA (1998)Maternal
epigenetics and methyl supplements affect agouti gene ex-
pression in Avy/a mice. FASEB J 12:949–957
YanH, YuanW, Velculescu VE, Vogelstein B, KinzlerKW(2002)
Allelic variation in human gene expression. Science 297:1143
